Single-Centre Real-Life Experience of Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis

Marletta, Dario A; Murgia, Giulia; Cattaneo, Angelo; Carrera, Carlo Giovanni; Marzano, Angelo Valerio

doi:10.36849/jdd.6962

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, RWE data from Israel showed that at week 24 of treatment with guselkumab, 76/62/17% of patients achieved ΔPASI 75/90/100, respectively 27 . Similar results were documented from two recent studies showing a significant reduction of aPASI under guselkumab, with 86.4/64.4/42.4% and 82/68/44% achieving ΔPASI 75/90/100, respectively 28,29 . The efficacy of risankizumab was shown in another study that included 131 patients.…”

Section: Discussionsupporting

confidence: 75%

“…27 Similar results were documented from two recent studies showing a significant reduction of aPASI under guselkumab, with 86.4/64.4/42.4% and 82/68/44% achieving DPASI 75/90/100, respectively. 28,29 The efficacy of risankizumab was shown in another study that included 131 patients. At week 28, DPASI 75/90/100 was reached in 82.44/ 65.65/47.33% of patients and aPASI ≤2 in 83.21%.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Real‐world data show high efficacy of IL23 inhibitors guselkumab and risankizumab in psoriatic arthritis and difficult‐to‐treat areas

Vaiopoulos,

Dalamaga,

Katsimbri

et al. 2023

Int J Dermatology

View full text Add to dashboard Cite

BackgroundPsoriasis and psoriatic arthritis are chronic inflammatory skin and joint diseases requiring effective therapies. Although clinical studies have shown the efficacy of IL‐23 inhibitors, real‐world data are limited.MethodsWe conducted a single‐center retrospective Greek study enrolling patients with psoriatic arthritis and moderate‐to‐severe plaque psoriasis being treated at our multidisciplinary psoriasis outpatient clinic. Our aim was to investigate the efficacy and safety of IL‐23 inhibitors guselkumab and risankizumab. Additionally, we sought to determine the clinical characteristics affecting treatment response. Primary endpoints were the evaluation of absolute Psoriasis Area and Severity Index (aPASI) and Disease Activity Index for Psoriatic Arthritis (DAPSA) at week 24.ResultsFifty‐nine patients (55.9% male, 69.5% early onset) with a mean age of 51.7 years were included. Twenty‐four patients (40.7%) had a concomitant psoriatic arthritis. Obesity was the main comorbidity (49.2%) with a mean body mass index (BMI) of 31.3 kg/m2. Additional comorbidities were hypertension (44.1%), dyslipidemia (32.2%), and diabetes (18.6%). Only eight patients (13.6%) were naïve to previous systemic treatments, whereas 40 patients (67.8%) were bio‐experienced. A statistically significant improvement of aPASI and DAPSA was demonstrated after 4, 16, and 24 weeks of treatment (P < 0.05). IL23 blockers were also efficacious in difficult‐to‐treat areas. Clinical outcome was affected from previous treatment with biologics. Treatment response was the same between guselkumab and risankizumab (P > 0.05).ConclusionThis real‐world study confirms the efficacy and safety of guselkumab and risankizumab in psoriatic arthritis and psoriasis reported from clinical trials.

show abstract

Section: Discussionsupporting

confidence: 75%

Section: Discussionmentioning

confidence: 99%

Real‐world data show high efficacy of IL23 inhibitors guselkumab and risankizumab in psoriatic arthritis and difficult‐to‐treat areas

Vaiopoulos,

Dalamaga,

Katsimbri

et al. 2023

Int J Dermatology

View full text Add to dashboard Cite

show abstract

Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative Review

et al. 2023

View full text Add to dashboard Cite

The approved biologics targeting interleukin (IL)-23 p19 for the treatment of moderate-to-severe plaque psoriasis, including guselkumab, tildrakizumab, and risankizumab, have generally favorable safety profiles. The aim of the current review is to describe in detail the safety of these selective inhibitors. A literature search was performed using PubMed from inception to 1 November 2022, to identify clinical trials and real-world evidence publications using the keywords “guselkumab,” “tildrakizumab,” and “risankizumab.” Overall, the most common adverse events (AEs) associated with IL-23 p19 inhibitors in clinical trials were nasopharyngitis, headache, and upper respiratory tract infections. Rates of serious AEs and AEs of interest, including serious infections, nonmelanoma skin cancer (NMSC), malignancies excluding NMSC, major adverse cardiovascular events, and serious hypersensitivity reactions, were not increased with long-term use in clinical trials. Selectively targeting IL-23 p19 was also not associated with elevated risk of opportunistic infections, tuberculosis reactivation, oral candidiasis, or inflammatory bowel disease. Results from real-world studies were similar, supporting the safe long-term use of these biologics in a wider population of patients with psoriasis, including older patients, patients for whom multiple biologics failed, and those with comorbidities such as obesity, metabolic syndrome, cardiovascular disease, dyslipidemia, diabetes, hypertension, and psoriatic arthritis. This review is limited by the lack of direct comparisons among therapeutic agents due to differences among study designs and safety data reporting methods. In conclusion, the favorable safety profiles of IL-23 p19 inhibitors support their long-term use in the management of patients with moderate-to-severe psoriasis.

show abstract

Real-world Performance of a New Strategy for Off-Label Use of Guselkumab in Moderate to Severe Psoriasis: Super-Responder Patients as the Epitome of Efficacy and Optimisation

et al. 2023

View full text Add to dashboard Cite

Single-Centre Real-Life Experience of Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis

Cited by 3 publications

References 0 publications

Real‐world data show high efficacy of IL23 inhibitors guselkumab and risankizumab in psoriatic arthritis and difficult‐to‐treat areas

Real‐world data show high efficacy of IL23 inhibitors guselkumab and risankizumab in psoriatic arthritis and difficult‐to‐treat areas

Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative Review

Real-world Performance of a New Strategy for Off-Label Use of Guselkumab in Moderate to Severe Psoriasis: Super-Responder Patients as the Epitome of Efficacy and Optimisation

Contact Info

Product

Resources

About